Using telemedicine to improve symptoms in psoriatic arthritis
Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA): Implementation of PsOWellTM in PsA
NA · University of Pennsylvania · NCT05631223
This study is testing if regular telemedicine visits can help people with psoriatic arthritis manage their symptoms and improve their quality of life.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 87 (estimated) |
| Ages | 18 Years to 89 Years |
| Sex | All |
| Sponsor | University of Pennsylvania (other) |
| Locations | 2 sites (Philadelphia, Pennsylvania and 1 other locations) |
| Trial ID | NCT05631223 on ClinicalTrials.gov |
What this trial studies
This interventional study aims to evaluate the acceptability, feasibility, and effectiveness of structured telemedicine visits for patients with psoriatic arthritis (PsA). Over a two-year period, patients with active symptoms will participate in telemedicine sessions that utilize motivational interviewing techniques to encourage lifestyle changes. The program, PsOWellTM, is designed to help patients set personal health goals and improve their overall quality of life and disease management. The trial will be conducted at three centers: the University of Pennsylvania, University of Utah, and University of Oxford.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-89 with active psoriatic arthritis symptoms who are stable on their current therapy.
Not a fit: Patients who are planning to change their systemic treatment or have a PsAID score of 4 or lower may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life and disease management for patients with psoriatic arthritis.
How similar studies have performed: Other studies have shown promise in using telemedicine for chronic disease management, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Population: Patients with Psoriatic Arthritis * Age 18-89. * Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score \>4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10). * Patients should be stable on therapy (i.e., not planning to switch therapy at the current visit). * Meet CASPAR criteria. * Provision of signed and dated informed consent form. * Willingness to comply with all study procedures and availability for duration of the study. * Has access to a mobile phone or other mobile device. Exclusion Criteria: * Inability to provide informed consent. * Plan to change systemic treatment for psoriasis or PsA in the next 4-8 weeks. * PsAID score ≤4
Where this trial is running
Philadelphia, Pennsylvania and 1 other locations
- University Of Pennsylvania — Philadelphia, Pennsylvania, United States (RECRUITING)
- University of Utah — Salt Lake City, Utah, United States (RECRUITING)
Study contacts
- Principal investigator: Alexis Ogdie-Beatty, MD — University of Pennsylvania
- Study coordinator: Sarah Hopkins Gillespie
- Email: Sarah.Hopkins@Pennmedicine.upenn.edu
- Phone: (215) 614-1840
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Psoriatic Arthritis